ArticleMikrochimica acta2026
Disposable electrochemical panel immunosensing systems for the simultaneous detection of potential biomarkers of ovarian cancer.
Article in Mikrochimica acta, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Rapid, low-cost, practical, disposable electrochemical panel immunosensor systems were developed for the individual and simultaneous determination of anterior gradient-2 protein (AGR2), folate receptor alpha (FOLR1), glycodelin (GLY), and soluble mesothelin-associated protein (SMRP), which are significantly increased in physiological fluids, particularly in ovarian cancer, and are potential biomarkers in the diagnosis of specific cancer types. To reduce the cost of the panel immunosensor system, the electrodes were hand-fabricated (HSPE), and then the HSPE surfaces were modified with gold nanoparticles (AuNPs). Surface analyses (SEM, XPS, FTIR) have confirmed that the sensor was manufactured robustly. The electrochemical characterization and analysis of the immunosensors were performed using electrochemical impedance spectroscopy, cyclic voltammetry, and differential pulse voltammetry methods. Optimal operating conditions (antibody concentration, antigen, and antibody incubation times) were determined for the prepared single immunosensors. Detection limits, linear detection ranges, selectivity, shelf lives, repeatability, and reproducibility of single and panel immunosensors were determined. The clinical validity of the multi-platform was confirmed by recoveries of over 95% in human serum samples and by ELISA. In this study, low-cost electrochemical panel systems that enable the simultaneous determination of AGR2, GLY, FOLR1, and SMRP biomarkers with high selectivity and accuracy, a wide linear range (1-500 pg mL⁻¹), low detection limits, and good reproducibility were produced for the first time.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.